SCHEMBL16058509

SCHEMBL16058509

CNCC(O)COc1cccc(Br)c1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.71
ALDH1A1 P00352 1/20 0.60
KMT2A Q03164 1/20 0.60
ADRB2 P07550 3/20 0.52
ADRB1 P08588 3/20 0.52
ALOX15 P16050 1/20 0.50
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA9 Q16790 2/20 0.48
MAPT P10636 1/20 0.48
CYP2D6 P10635 2/20 0.48
ADRB3 P13945 1/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
HIF1A Q16665 1/20 0.48
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16059747 1.00 KDM4E (0.71) KDM4EALDH1A1KMT2AADRB2ADRB1
SCHEMBL16058956 1.00 KDM4E (0.71) KDM4EALDH1A1KMT2AADRB2ADRB1
SCHEMBL22640088 0.83 KDM4E (1.00) KDM4EALDH1A1KMT2AADRB2ADRB1
SCHEMBL22640124 0.83 KDM4E (1.00) KDM4EALDH1A1KMT2AADRB2ADRB1
SCHEMBL14027336 0.83 ALDH1A1 (0.54) KDM4EALDH1A1KMT2AADRB2ADRB1
SCHEMBL17622913 0.82 KDM4E (0.71) KDM4EADRB2ADRB1ALOX15CA12
SCHEMBL3229817 0.81 TSHR (0.66) KDM4EALDH1A1KMT2ATSHRMAPK1
SCHEMBL3229807 0.81 TSHR (0.66) KDM4EALDH1A1KMT2ATSHRMAPK1
SCHEMBL16090435 0.80 ADRB1 (0.70) KDM4EALDH1A1KMT2AADRB2ADRB1
SCHEMBL6262690 0.80 ADRB1 (0.70) KDM4EALDH1A1KMT2AADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416263-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2023-12-28 US disclosed
US-11834455-B2 Carm1 inhibitors and uses thereof Epizyme, Inc. (US) 2023-12-05 US disclosed
US-11834455-B2 Carm1 inhibitors and uses thereof Epizyme, Inc. (US) 2023-12-05 US disclosed
US-20230279020-A9 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2023-09-07 US disclosed
US-20230279020-A9 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2023-09-07 US disclosed
US-20210155631-A1 CARM1 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2021-05-27 US disclosed
US-10633389-B2 CARM1 inhibitors and uses thereof Epizyme, Inc. (US) 2020-04-28 US disclosed
US-20190135819-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. 2019-05-09 US disclosed
US-10118931-B2 CARM1 inhibitors and uses thereof Epizyme, Inc. (US) 2018-11-06 US disclosed
US-20180282343-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. 2018-10-04 US disclosed
US-20170320883-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. 2017-11-09 US disclosed
US-20170320883-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. 2017-11-09 US disclosed
US-9738651-B2 CARM1 inhibitors and uses thereof Epizyme, Inc. (US) 2017-08-22 US disclosed
US-9738651-B2 CARM1 inhibitors and uses thereof Epizyme, Inc. (US) 2017-08-22 US disclosed
WO-2016044641-A2 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-03-24 WO disclosed
US-20160039834-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-02-11 US disclosed
US-20160039834-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-02-11 US disclosed
EP-2970219-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-01-20 EP disclosed
WO-2014144169-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-09-18 WO disclosed
WO-2014144169-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155631-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 KDM4E 1082/4885ALDH1A1 2206/4885KMT2A 43/4885
US-10118931-B2 CARM1 inhibitors and uses thereof CARM1, TIAM1, ADRM1 KDM4E 1082/4885ALDH1A1 2206/4885KMT2A 43/4885
US-20230279020-A9 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 KDM4E 1082/4885ALDH1A1 2206/4885KMT2A 43/4885
US-20170320883-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 KDM4E 1077/4885ALDH1A1 2184/4885KMT2A 43/4885
US-11834455-B2 Carm1 inhibitors and uses thereof CARM1, TIAM1, ADRM1 KDM4E 1077/4885ALDH1A1 2184/4885KMT2A 43/4885
US-10633389-B2 CARM1 inhibitors and uses thereof CARM1, TIAM1, ADRM1 KDM4E 1082/4885ALDH1A1 2206/4885KMT2A 43/4885
US-20190135819-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 KDM4E 1082/4885ALDH1A1 2206/4885KMT2A 43/4885
US-20230416263-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 KDM4E 1082/4885ALDH1A1 2206/4885KMT2A 43/4885
US-20180282343-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 KDM4E 1077/4885ALDH1A1 2184/4885KMT2A 43/4885
US-20160039834-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 KDM4E 1195/4885ALDH1A1 2226/4885KMT2A 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.